Axsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results, Beats Expectations By $0.43 EPS

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.43, Zacks reports. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Axsome Therapeutics Trading Down 0.0 %

NASDAQ:AXSM opened at $112.21 on Monday. The company has a market capitalization of $5.52 billion, a P/E ratio of -18.73 and a beta of 0.46. The stock's 50 day moving average price is $113.58 and its 200 day moving average price is $104.02. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on AXSM shares. Jefferies Financial Group assumed coverage on Axsome Therapeutics in a report on Monday, April 7th. They issued a "buy" rating and a $200.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $200.00 price target on shares of Axsome Therapeutics in a research note on Thursday, April 3rd. Bank of America upped their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Truist Financial lifted their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Finally, Needham & Company LLC restated a "buy" rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $169.87.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 22.40% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.